Recently, Viva Biotech has participated in several prominent industry events both domestically and internationally, including the T20 BIO TONACEA Conference, CBA-China Annual Conference, ADC x XDC China Forum, CPHI China, and the San Diego MedChem Symposium. At these high-profile events, Viva Biotech showcased its deep expertise and innovative concepts in the biopharmaceutical field through expert presentations, booth exhibitions, and award recognition, fostering in-depth industry exchanges and collaborations. What captivating insights and forward-looking perspectives did the experts bring? Let's delve in and find out.

Domestic Conferences

The T20 BIO TONACEA Conference

The T20 BIO TONACEA Conference grandly opened at the Kempinski Hotel Suzhou, bringing together numerous experts and scholars from the industry. Participants gathered to discuss the theme of "The Future of Pharmaceutical Innovation in China," exploring cutting-edge technologies, industry trends, and shared experiences in the field of biopharmaceuticals.

Viva Biotech was invited to participate in this exhibition, showcasing the company's one-stop CRO/CDMO service capabilities. Additionally, Dr. Han Dai, Chief Innovation Officer (CIO) of Viva Biotech and Head of the Viva BioInnovatior, was invited as a special guest and chaired a roundtable discussion titled "The Opportunities and Limitations of Upstream Pharmaceutical Research". Dr. Dai delved into topics as the development potential, technical constraints, and innovative opportunities in the upstream sector of new drug R&D with other industry experts such, providing attendees with comprehensive and profound industry insights.

First from left: Dr. Han Dai, CIO of Viva Biotech and Head of Viva BioInnovator

During the exhibition, the Viva Biotech’s team warmly welcomed guests at the booth, sharing in-depth insights and successful experiences in new drug development and manufacturing. The team showcased a range of cutting-edge technology platforms, including the XDC platform, PROTAC/molecular glue technology platform, protein production and structural research, membrane protein research, cryo-EM, drug screening, Bioassays, DMPK, AIDD/CADD, and therapeutic antibody discovery on booth. These platforms highlighted the company's innovative capabilities in biopharmaceutical R&D. Faced with a diverse range of R&D inquiries from booth visitors, Viva Biotech's expert team delivered not only highly targeted and practical solutions but also actively engaged in discussion about groundbreaking research ideas, collectively pushing the boundaries of innovation. The team's technical prowess and innovative concepts garnered significant praise from attendees. We anticipate future industry events, where we can collaborate with more partners to explore emerging trends and drive advancements in global pharmaceutical innovation.

CBA-China Annual Conference

The First Chinese biopharmaceutical Association CBA-China Annual Conference (CBA), was recently held at the Suzhou International Expo Center. Viva Biotech, a leading one-stop CRO/CDMO service company, was invited to participate in this conference. Viva Biotech attracted numerous industry professionals for in-depth discussions and consultations at booth, where the business team warmly welcomed visitors and provided detailed introductions to the company's extensive experience and unique insights in drug development and manufacturing.

Attendees showed strong interest in Viva Biotech's XDC technology and large molecule services. Addressing these key topics, Viva team provided an in-depth explanation of the company's technological advantages in AI+XDC and AI+biologics/antibody drug discovery. They elaborated on the application of AIDD/CADD technology in optimizing drug design, enhancing druggability and efficacy, and demonstrated their exceptional capabilities in ADC design and peptide drug optimization. In the field of biologics/antibody discovery, Viva Biotech employs structure-based drug design (SBDD) approaches combined with AI, accumulating extensive experience in antibody discovery, engineering, and affinity maturation.

3rd ADC x XDC China Forum 2024

Recently, the 3rd ADC x XDC China Forum 2024 was successfully held at the Crowne Plaza Shanghai Pujiang. Dr. Xinyu Deng, Vice President of Biology at Viva Biotech (Shanghai), was invited to attend the conference and participated as a host in the roundtable discussion titled "Connecting Everything: Challenges and Opportunities in XDC." The discussion covered topics such as the differences and development trends between XDC and traditional ADC, the potential of new PDC drug development, the market prospects for RDC, and the challenges they face. The interaction among the panelists highlighted the burgeoning development of the XDC industry in China and its innovation potential, generating many new ideas and perspectives during the discussions. We look forward to seeing more innovative XDC products successfully launched and going global, and we hope that Viva Biotech can collaborate with more industry partners to make progress.

First from left: Dr. Xinyu Deng, Vice President of Biology at Viva Biotech (Shanghai)

Oversea Conferences Review

CPHI China 2024

Recently, Langhua Pharmaceutical, a subsidiary of Viva Biotech, participated in the 22nd CPHI China 2024. Invited to attend this gathering, Langhua Pharmaceutical stood out and was awarded the "API Development & Innovation Award." This honor not only recognizes Langhua Pharmaceutical's exceptional performance in API development and innovation but also underscores Viva Biotech's significant role in innovatively advancing CDMO services.

The 25th Annual San Diego MedChem Symposium 2024

On July 12th, Viva Biotech participated in the 25th Annual San Diego MedChem Symposium held at the University of California San Diego. Viva Biotech's booth attracted numerous attendees who actively inquired about and discussed potential collaboration opportunities. Ms. Yinghong Gao, Vice President of Viva Biotech, shared the company's capabilities in drug chemistry and synthetic chemistry driven by AIDD/CADD, focusing on small molecules, PROTACs, peptides, and antibody-drug conjugates (ADCs). She also showcased the company's one-stop drug discovery platform. This symposium not only demonstrated Viva Biotech's strength in the field of drug research and development but also further promoted industry exchanges and collaborations.